A Perth-based biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies aimed at improving treatment for diabetes beyond current injectable options such as Ozempic. The companies are focusing on next-generation approaches to diabetes management, including therapies intended to address insulin resistance, rather than relying solely on existing drug classes.
Across reporting from multiple outlets, the companies also say they are establishing Australia’s first dedicated RNA facility. The facility is described as part of their effort to support RNA research and development, with the broader goal of advancing RNA therapeutic work from development through future clinical use.
The coverage is consistent in naming the two companies and outlining both main tracks: development of RNA-based diabetes therapies and construction of a national-scale RNA capability through the new facility. None of the articles provide additional trial results, timelines, or regulatory details; the emphasis is on the companies’ research direction and infrastructure plans as they pursue potential treatments targeting diabetes mechanisms.
